Literature DB >> 28595287

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Danna Jennings1, Andrew Siderowf2, Matthew Stern3, John Seibyl1, Shirley Eberly4, David Oakes4, Kenneth Marek1.   

Abstract

Importance: Detecting individuals at risk for Parkinson disease (PD) during the prodromal phase could clarify disease mechanisms and allow for treatment earlier in the disease process to possibly slow or prevent the onset of motor PD. Objective: To determine if the combination of smell identification testing followed by dopamine transporter (DAT) imaging can accurately and efficiently identify individuals from the general population at risk for conversion to a clinical diagnosis of PD. Design, Setting, and Participants: Participants were identified from the community by olfactory testing assessed longitudinally with DAT imaging 2 and 4 years after baseline and by annual clinical follow-up to determine whether they had clinical evidence to establish a PD diagnosis. Participants were contacted by mail and completed olfactory testing at home. Longitudinal follow-up of clinical measures and DAT imaging occurred at specialty centers. There were 203 hyposmic and 100 normosmic participants. A total of 185 hyposmic and 95 normosmic individuals had at least 1 follow-up visit, and 152 hyposmic participants (82.2%) were either observed for 4 years or converted to PD during follow-up. Main Outcomes and Measures: Percentage of individuals with hyposmia and a DAT deficit that converted to PD and the change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imaging during 4-year follow-up.
Results: Of 280 total participants, 140 (50.0%) were male, and the mean (SD) age of the cohort was 63 (8.7) years. Among 21 participants with hyposmia and a DAT deficit (65% or less of age-expected lowest putamen binding ratio) at baseline, 14 (67%) converted to PD at 4 years compared with 2 of 22 participants (9%) with a DAT in an indeterminate range (greater than 65%-80%) and 3 of 109 participants (2.8%) with no DAT deficit (greater than 80%) at baseline. Individuals with a baseline DAT deficit experienced a 4-year decline in DAT binding of 20.23% (SD, 15.04%) compared with 3.68% (SD, 18.36%) and 5.45% (SD, 13.58%) for participants with an indeterminate and no DAT deficit, respectively (P = .002). The relative risk of conversion to a diagnosis of PD in hyposmic individuals with a DAT deficit was 17.47 (95% CI, 7.02-43.45) compared with individuals with either indeterminate or no DAT deficit. Conclusions and Relevance: The combination of hyposmia and DAT deficit was highly predictive of conversion to PD within 4 years of clinical follow-up. Individuals with hyposmia and a DAT deficit had a 5% reduction in DAT binding annually, similar to early PD. These results provide a framework for planning disease prevention studies in PD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28595287      PMCID: PMC5710321          DOI: 10.1001/jamaneurol.2017.0985

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  28 in total

Review 1.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

2.  Association of olfactory dysfunction with risk for future Parkinson's disease.

Authors:  G Webster Ross; Helen Petrovitch; Robert D Abbott; Caroline M Tanner; Jordan Popper; Kamal Masaki; Lenore Launer; Lon R White
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

3.  Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell.

Authors:  H W Berendse; J Booij; C M Francot; P L Bergmans; R Hijman; J C Stoof; E C Wolters
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

4.  Frequency of bowel movements and the future risk of Parkinson's disease.

Authors:  R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

5.  Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.

Authors:  Maria Sierra; Pascual Sánchez-Juan; María Isabel Martínez-Rodríguez; Isabel González-Aramburu; Inés García-Gorostiaga; María Remedios Quirce; Enrique Palacio; José Manuel Carril; José Berciano; Onofre Combarros; Jon Infante
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

6.  A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.

Authors:  Bernard Ravina; Caroline Tanner; Diane Dieuliis; Shirley Eberly; Emily Flagg; Wendy R Galpern; Stanley Fahn; Christopher G Goetz; Stephen Grate; Roger Kurlan; Anthony E Lang; Kenneth Marek; Karl Kieburtz; David Oakes; Robin Elliott; Ira Shoulson
Journal:  Mov Disord       Date:  2009-10-30       Impact factor: 10.338

7.  Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Authors:  Vicky L Marshall; Cornelia B Reininger; Moritz Marquardt; Jim Patterson; Donald M Hadley; Wolfgang H Oertel; Hani T S Benamer; Paul Kemp; David Burn; Eduardo Tolosa; Jamie Kulisevsky; Luis Cunha; Durval Costa; Jan Booij; Klaus Tatsch; K Ray Chaudhuri; Gudrun Ulm; Oliver Pogarell; Helmut Höffken; Anja Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

8.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.

Authors:  Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria
Journal:  Lancet Neurol       Date:  2013-04-03       Impact factor: 44.182

9.  Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.

Authors:  R L Doty; D A Deems; S Stellar
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  46 in total

Review 1.  Nigrosome 1 imaging: technical considerations and clinical applications.

Authors:  Eung Yeop Kim; Young Hee Sung; Jongho Lee
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

Review 2.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

Review 3.  Biomarkers for Parkinson's Disease: How Good Are They?

Authors:  Tianbai Li; Weidong Le
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

Review 4.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

5.  Cognition and the course of prodromal Parkinson's disease.

Authors:  Daniel Weintraub; Lana M Chahine; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings
Journal:  Mov Disord       Date:  2017-10-24       Impact factor: 10.338

Review 6.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

7.  Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.

Authors:  Rui Liu; David M Umbach; Alexander I Tröster; Xuemei Huang; Honglei Chen
Journal:  Parkinsonism Relat Disord       Date:  2020-02-11       Impact factor: 4.891

Review 8.  Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.

Authors:  Monica Javidnia; Mark Frasier; Ira Shoulson; Ibrahim Turkoz; Kumar Budur
Journal:  Innov Clin Neurosci       Date:  2020-01-01

Review 9.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

10.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Authors:  Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek
Journal:  Lancet Neurol       Date:  2019-10-31       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.